evidence: The new vaccines that protect older adults against respiratory syncytial virus, or RSV, may be linked to a small increased risk of developing Guillain-Barré syndrome, new data from the Centers for Disease Control and Prevention and the Food and Drug Administration suggest. [...] There have been concerns the new RSV vaccines, which were first brought to market last fall, might carry an increased risk of GBS after three cases were detected among people in the vaccine arms of the clinical trials Pfizer and GSK conducted to persuade the FDA to license the products. [...] CDC vaccine experts told the ACIP that a risk-benefit analysis the agency conducted continues to support use of the vaccines in people aged 60 and older, because of the burden of RSV disease in that population. For every 1 million doses of RSV vaccine given, between 2,400 and 2,700 RSV hospitalizations, 450 to 520 intensive care unit admissions, and 120 to 140 deaths are averted, the agency estimated.